Preliminary Results from a Prospective Study Comparing White Blood Cell and Neutrophil Counts from a Laboratory to Those Measured with a New Device in Patients with Breast Cancer

Anna C Lohman, Ingrid VAN Rijn, Christina L Lindhardt, Reinhard Vonthein, Dirk Rades, Niels Henrik Holländer

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

BACKGROUND/AIM: If blood tests were performed at home, unnecessary trips of patients for chemotherapy could be avoided. The HemoCue® WBC DIFF device was tested at home by 14 patients with breast cancer.

MATERIALS AND METHODS: A total of 42 measurements of white blood cell (WBC) and neutrophil counts with the device at home were compared to laboratory measurements performed within 3 hours. Bland-Altman plots were created for limits of agreement that should be less than 1.0×109/l for WBC and 0.5×109/l for neutrophils to indicate a similar grade of intensity.

RESULTS: Limits of agreement were -1.61×109/l and +2.34×109/l for WBC and -1.15×109/l and +1.39×109/l for neutrophils. All patients considered the device advantageous, particularly because they did not have to travel or wait for results. Most patients experienced problems with the lancet when taking blood samples.

CONCLUSION: Disagreement of WBC and neutrophil counts between methods appeared clinically relevant. Findings need to be verified in a larger cohort, including the use of a different type of lancet.

Original languageEnglish
JournalIn Vivo
Volume32
Issue number5
Pages (from-to)1283-1288
ISSN0258-851X
DOIs
Publication statusPublished - 29. Aug 2018
Externally publishedYes

Fingerprint

Neutrophils
Blood
Cells
Prospective Studies
Equipment and Supplies
Chemotherapy

Keywords

  • Breast cancer patients
  • Chemotherapy
  • Neutrophil counts
  • New device
  • Preliminary results
  • White blood cell counts

Cite this

Lohman, Anna C ; VAN Rijn, Ingrid ; Lindhardt, Christina L ; Vonthein, Reinhard ; Rades, Dirk ; Holländer, Niels Henrik. / Preliminary Results from a Prospective Study Comparing White Blood Cell and Neutrophil Counts from a Laboratory to Those Measured with a New Device in Patients with Breast Cancer. In: In Vivo. 2018 ; Vol. 32, No. 5. pp. 1283-1288.
@article{175f05ea4ed94cf4b338bdabf08be130,
title = "Preliminary Results from a Prospective Study Comparing White Blood Cell and Neutrophil Counts from a Laboratory to Those Measured with a New Device in Patients with Breast Cancer",
abstract = "BACKGROUND/AIM: If blood tests were performed at home, unnecessary trips of patients for chemotherapy could be avoided. The HemoCue{\circledR} WBC DIFF device was tested at home by 14 patients with breast cancer.MATERIALS AND METHODS: A total of 42 measurements of white blood cell (WBC) and neutrophil counts with the device at home were compared to laboratory measurements performed within 3 hours. Bland-Altman plots were created for limits of agreement that should be less than 1.0×109/l for WBC and 0.5×109/l for neutrophils to indicate a similar grade of intensity.RESULTS: Limits of agreement were -1.61×109/l and +2.34×109/l for WBC and -1.15×109/l and +1.39×109/l for neutrophils. All patients considered the device advantageous, particularly because they did not have to travel or wait for results. Most patients experienced problems with the lancet when taking blood samples.CONCLUSION: Disagreement of WBC and neutrophil counts between methods appeared clinically relevant. Findings need to be verified in a larger cohort, including the use of a different type of lancet.",
keywords = "Breast cancer patients, Chemotherapy, Neutrophil counts, New device, Preliminary results, White blood cell counts",
author = "Lohman, {Anna C} and {VAN Rijn}, Ingrid and Lindhardt, {Christina L} and Reinhard Vonthein and Dirk Rades and Holl{\"a}nder, {Niels Henrik}",
note = "Copyright{\circledC} 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.",
year = "2018",
month = "8",
day = "29",
doi = "10.21873/invivo.11378",
language = "English",
volume = "32",
pages = "1283--1288",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "5",

}

Preliminary Results from a Prospective Study Comparing White Blood Cell and Neutrophil Counts from a Laboratory to Those Measured with a New Device in Patients with Breast Cancer. / Lohman, Anna C; VAN Rijn, Ingrid; Lindhardt, Christina L; Vonthein, Reinhard; Rades, Dirk; Holländer, Niels Henrik.

In: In Vivo, Vol. 32, No. 5, 29.08.2018, p. 1283-1288.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Preliminary Results from a Prospective Study Comparing White Blood Cell and Neutrophil Counts from a Laboratory to Those Measured with a New Device in Patients with Breast Cancer

AU - Lohman, Anna C

AU - VAN Rijn, Ingrid

AU - Lindhardt, Christina L

AU - Vonthein, Reinhard

AU - Rades, Dirk

AU - Holländer, Niels Henrik

N1 - Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

PY - 2018/8/29

Y1 - 2018/8/29

N2 - BACKGROUND/AIM: If blood tests were performed at home, unnecessary trips of patients for chemotherapy could be avoided. The HemoCue® WBC DIFF device was tested at home by 14 patients with breast cancer.MATERIALS AND METHODS: A total of 42 measurements of white blood cell (WBC) and neutrophil counts with the device at home were compared to laboratory measurements performed within 3 hours. Bland-Altman plots were created for limits of agreement that should be less than 1.0×109/l for WBC and 0.5×109/l for neutrophils to indicate a similar grade of intensity.RESULTS: Limits of agreement were -1.61×109/l and +2.34×109/l for WBC and -1.15×109/l and +1.39×109/l for neutrophils. All patients considered the device advantageous, particularly because they did not have to travel or wait for results. Most patients experienced problems with the lancet when taking blood samples.CONCLUSION: Disagreement of WBC and neutrophil counts between methods appeared clinically relevant. Findings need to be verified in a larger cohort, including the use of a different type of lancet.

AB - BACKGROUND/AIM: If blood tests were performed at home, unnecessary trips of patients for chemotherapy could be avoided. The HemoCue® WBC DIFF device was tested at home by 14 patients with breast cancer.MATERIALS AND METHODS: A total of 42 measurements of white blood cell (WBC) and neutrophil counts with the device at home were compared to laboratory measurements performed within 3 hours. Bland-Altman plots were created for limits of agreement that should be less than 1.0×109/l for WBC and 0.5×109/l for neutrophils to indicate a similar grade of intensity.RESULTS: Limits of agreement were -1.61×109/l and +2.34×109/l for WBC and -1.15×109/l and +1.39×109/l for neutrophils. All patients considered the device advantageous, particularly because they did not have to travel or wait for results. Most patients experienced problems with the lancet when taking blood samples.CONCLUSION: Disagreement of WBC and neutrophil counts between methods appeared clinically relevant. Findings need to be verified in a larger cohort, including the use of a different type of lancet.

KW - Breast cancer patients

KW - Chemotherapy

KW - Neutrophil counts

KW - New device

KW - Preliminary results

KW - White blood cell counts

U2 - 10.21873/invivo.11378

DO - 10.21873/invivo.11378

M3 - Journal article

C2 - 30150458

VL - 32

SP - 1283

EP - 1288

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 5

ER -